Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-11-14
1999-06-22
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514399, 514646, 514402, 5483351, 5483355, 5483365, 558436, A61K 31415, C07D23354
Patent
active
059143436
ABSTRACT:
The present invention features compounds and methods for inhibiting hyper-proliferative cell growth. The compounds and method are preferably used to treat patients having a hyperproliferative cell disorder.
REFERENCES:
patent: 4087535 (1978-05-01), Heubach et al.
patent: 4284786 (1981-08-01), Kammerer et al.
patent: 4351841 (1982-09-01), Kammerer et al.
patent: 4992271 (1991-02-01), Fernandez et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5268382 (1993-12-01), Bartlett et al.
patent: 5314685 (1994-05-01), Tyle et al.
patent: 5476866 (1995-12-01), Kuo et al.
patent: 5506249 (1996-04-01), Kuo et al.
patent: 5760066 (1998-06-01), Tang
Axton et al., "Novel Immunosuppressive Butenamides," J. Chem. Soc. Perkin Trans. I pp. 2203-2213 (1992).
Bartlett et al., "Effects of leflunomide on immune responses and models of inflammation," Springer Seminars in Immunopathology 14:381-394 (1993).
Bartlett et al., "Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection," Agents and Actions 32:10-21 (1991).
Bartlett et al., "Leflunomide: A Novel Immunomodulating Drug," in Nonsteroidal Anti-Inflammatory Drugs, 2nd edition, Lewis and Furstk eds., Dekker, New York, New York, pp. 349-366.
Baselga et al., "Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal Antibodies," J. of Natl. Cancer Institute 85(16):1327-1333 (1993).
Baudy et al., "Potent Quinoxaline-Spaced Phosphono .alpha.-Amino Acids of the AP-6 Type as Competitive NMDA Antagonists: Synthesis and Biological Evaluation," J. Med. Chem. 36:331-342 (1993).
Bilder et al., "Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells," Am. J. Physiol. 260(Cell Physiol.29):C721-C730 (1991).
Birchall et al., "Compositions for killing internal parasites containing 3-tert-alkyl-4-hydroxy-5-halobenzylidene-malononitriles," Chemical Abstracts 88:535 at 104957a (1978).
Borisevich et al., "Reaction of arylamides of hydroxylamine and substituted hydrazines," Chemical Abstracts 107(7):726 at abstract No. 58919a (Aug. 17, 1987).
Borisevich et al., "Reaction of arylamides of hydroxylamine and substituted hydrazines," Ukr. Khim. Zh. 52(6):641-647 (1986).
Bryckaert et al., "Inhibition of Platelet-Derived Growth Factor-Induced Mitogenesis and Tyrosine Kinase Activity in Cultured Bone Marrow Fibroblasts by Tyrphostins," Exp. Cell Research 199:255-261 (1992).
Bustelo and Barbacid, "Tyrosine Phosphorylation of the vav Proto-Oncogene Product in Activated B Cells," Science 256:1196-1199 (1992).
Caraglia et al., "Cytosine arabinoside increases the binding of .sup.125 I-labelled epidermal growth factor and .sup.125 I-transferrin and enhances the in vitro targeting of human tumour cells with anti-(growth factor receptor)mAb," Cancer Immunol. Immunother. 37:150-156 (1993).
Carboni et al., "Cyanocarbon Chemistry. XI. Malononitrile Dimer," J. Am. Chem. Soc. 80:2838-2840 (1958).
Cecil Textbook of Medicine eds. Wyngaarden, Smith, Bennett, W.B. Saunders p. 2220 (1992).
Chen and Okayama, "Calcium Phosphate-Mediated Gene Transfer: A Highly Efficient Transfection System for Stably Transforming Cells with Plasmid DNA," BioTechniques 6:632-638 (1988).
Cherwinski et al., "The immunosuppressant Leflunomide Inhibits Lymphocyte Progression Through Cell Cycle by a Novel Mechanism," The Journal of Pharamology and Experimental Therapeutice 272:460-468 (1995).
Chong et al., "Leflumonide, a Novel Immunomodulatory Agent: In Vitro Analyses of the Mechanism of Immunosuppression," Transplation Proceedings 25:747-749 (1993).
Chong et al., "Leflunomide, A Novel Immunosuppressive Agent: The Mechanism of Inhibition of T Cell Proliferation," Transplantation 55:1361-1366 (1993).
Conn et al., "Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-dervied cell line," Proc. Natl. Acad. Sci. USA 87:1323-1327 (1990).
Dati et al., "Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells," Oncogene 5:1001-1006 (1990).
Decker and Lohmann-Matthes, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," J. Immunol. Methods 15:61-69 (1988).
Ehrlich and Bogert, "Experiments in the Veratrole and Quinoxaline Groups," J. Org. Chem. 12:522-534 (1947).
Ferris et al., "Synthesis of Quinazoline Nucleosides from Ribose and Anthranilonitrile. Application of Phase-Transfer Catalysis in Nucleoside Synthesis," J. Org. Chem. 44(2):173-178 (1979).
Floege et al., "Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo," Kidney International 43:S47-S54 (1993).
Fry et al., "New insights into protein-tyrosine kinase receptor signaling complexes," Protein Science 2:1785-1797 (1993).
Gazit et al., "Tyrphostins 1. Synthesis and Biological Activity of Protein Tyrosine Kinase Inhibitors," J. Med. Chem. 32:2344-2352 (1989).
Gazit et al., "Tyrphostins. 2. Heterocyclic and .alpha.-Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2
eu Tyrosine Kinases," J. Med. Chem. 34:1896-1907 (1991).
Gazit et al., "Tyrphostins. 3. Structure-Activity Relationship Studies of a .alpha.-Substituted Benzylidenemalononitrile 5-S-Aryltyrphostins," J. Med. Chem. 36:3556-3564 (1993).
Glant et al., "Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide," Immunopharmacology 23:105-116 (1992).
Gottardis et al., "Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumoristatic Action of Tamoxifen," J. Steroid Biochem. 30(1-6):311-314 (1988).
Gulbins et al., "Tyrosine Kinase-Stimulated Guanine Nucleotide Exchange Activity of Vav in T Cell Activation," Science 260:822-825 (1993).
Hale et al., "Prognostic value of epidermal growth factor receptor expression in cervical carcinoma," J. Clin. Pathol. 46:149-153 (1993).
Hambleton and McMahon, "Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis," Agents and Actions 29:328-332 (1990).
Harris et al., "Breast Cancer (First of Three Parts)," New England J. of Medicine 327(5):318-328 (1992).
Heldin, "Structural and functional studies on platelet-derived growth factor," EMBO Journal 11:4251-4259 (1992).
Hoekstra et al., "Differential effects of steurosporine and tyrphostins on receptor tyrosine kinase autophosphorylation and peptide substrate phosphorylation," Experimental Therapeutics from 84th Annual Meeting of American Association for Cancer Research, vol. 34, abstract No. 2455 (1993).
Honegger et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," Cell 5:199-209 (1987).
Houck et al., "The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA," Molecular Endocrinology 5:1806-1814 (1991).
Issidorides and Haddadin, "Benzofurazan Oxide. II. Reactions with Enolate Anions," J. Org. Chem. 31:4067-4068 (1966).
Ju et al., "Leflunomide inhibits cytokine-induced DNA synthesis of rabbit synovial cells in culture," Acta Pharmacologica Sinica 15:223-226 (1994).
Ju et al., "Leflunomide Inhibits PAF Induced DNA Synthesis In Rabbit Synovial Cells and PAF Production From Rat Peritoneal Macrophages," Acta Pharamaceutica Sinica 92:90-94 (1994).
Karameris et al., "Expression of Epidermal Growth Factor (EGF) and Epidermal Growth Factor Receptor (EGFR) in Gastric and Colorectal Carcinomas: An Immunohistological Study of 63 Cases," Path. Res. Pract. 189:133-137 (1993).
Koenders et al., "Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study," Breast Cancer Research and Treatment 25:21-27 (1993).
Korzeniewski and Callewaert, "An Enzyme-Release Assay for Natural Cytotoxicity.sup.1," J. Immunol. Methods 64:313-320 (1983).
Kuchle et al., "Prevention of Kidney and Skin Graft Rejection in Rats by Lef
Richter Johann
Sackey Ebenezer
Sugen Inc.
LandOfFree
Compounds and methods for inhibiting hyper-proliferative cell gr does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for inhibiting hyper-proliferative cell gr, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for inhibiting hyper-proliferative cell gr will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1708381